Ramsdell’s Verdict: Why Biotech Out-Innovates Academia

Nobel laureate Fred Ramsdell, who shared the 2023 prize for discoveries on regulatory T cells, has launched a sharp critique of university-based medical research. Speaking at the Lindau Nobel Laureate Meeting, the immunologist contended that biotech companies, not academic institutions, are now the true engines of transformative science. His reasoning is structural: corporate labs operate as tightly integrated teams with a shared, disease-focused goal, while university principal investigators are pulled in conflicting directions by the need to secure grants and publish in top journals.

Ramsdell’s own career trajectory underscores the distinction. After a postdoctoral fellowship, he joined Immunex in Seattle, where he felt that the company’s team-oriented culture—bringing together biochemists, molecular biologists, and protein structure experts—provided an “engine” that no single university lab could replicate. “Most people at universities do collaborate but they don’t operate as a team – they really don’t,” he said, adding that the primary shared objective in academia is often just to get funded, rather than to push a therapy into human trials.

He acknowledged that the biotech model has its cruel side. The very focus that drives innovation also makes research programs disposable. Ramsdell’s own Nobel-winning work was conducted at Darwin, a small biotech that was later shut down by its acquirer, Chiroscience, purely to save $10 million a year. Years later, Novo Nordisk closed his entire autoimmune disease division soon after he left, despite promising data. Such episodes illustrate a tension: the same corporate mindset that accelerates applied science can abruptly terminate lines of inquiry that might have borne fruit over a longer horizon.

Inside the Incentive Gap—and the Biotech Trap

The University Incentive Trap

Ramsdell’s core complaint is that academic researchers are not “incentivised to take risks” because funding and career advancement depend on producing a steady stream of high-impact journal papers. The pressure to win grants and maintain laboratories forces even brilliant scientists to play it safe, pursuing incremental advances rather than the kind of long-shot, foundational work that can lead to a Nobel-worthy breakthrough. This is not a new observation, but coming from a laureate who succeeded in both worlds, it carries weight.

Biotech’s Team Advantage—and Its Achilles Heel

The Immunex experience illustrates a genuine organizational edge: multidisciplinary teams working toward a single therapeutic goal with a speed and focus that university labs rarely match. Yet the story of Darwin and Novo Nordisk shows that biotech’s strength is also its vulnerability. When a project doesn’t align with near-term commercial targets, the spreadsheet can override the science. Ramsdell accepted that his discovery was still 20 years from a marketable drug, but for a publicly traded company, that timeline is often unacceptable. The result is a system that may discard precisely the kind of curiosity-driven research that originally fed the pipeline.

A Sector-Wide Pattern, Not Isolated Incidents

Ramsdell claimed that the majority of breakthroughs in his field during the 1990s came from biotech, not academia. While that statement is his personal assessment and not a rigorous data point, it mirrors a broader trend in drug development: many first-in-class therapies originate from small, focused biotechs that are later acquired or partnered. The implication is that universities, despite their intellectual depth, are losing ground as the primary originators of disease-modifying knowledge.

What Research Leaders and Universities Should Do With This Critique

For university research leaders and funding bodies:

  • Pilot new team structures that embed cross-disciplinary collaborators under a single, disease-focused mission, akin to the Immunex model Ramsdell described, and evaluate whether publication output, translation speed, or risk-taking behaviour improves.
  • Replace some individual grant schemes with programme-level awards that require a shared therapeutic goal and joint accountability across labs, directly addressing the “common goal other than to get funded” problem Ramsdell highlighted.
  • Create protected time and dedicated funding streams for high-risk, long-horizon projects that do not depend on annual paper counts—explicitly countering the “Nature papers every year” treadmill Ramsdell criticised.

For biotech executives and investors:

  • When making portfolio decisions, explicitly weigh the long-term foundational value of early-stage programmes against the immediate cost savings Ramsdell experienced at Darwin and Novo Nordisk. Institutionalise a stage-gate review that includes scientific merit, not just commercial timeline fit.
  • Consider hybrid academic partnerships that combine the team-engine approach with the longer time-horizons that universities can offer, reducing the risk that a project is killed solely because it is “far away from the mother ship”.